Thomson Peter G. 4
4 · Fulcrum Therapeutics, Inc. · Filed Feb 24, 2021
Insider Transaction Report
Form 4
Thomson Peter G.
See Remarks
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2021-02-22−5,000→ 50,471 totalExercise: $7.84Exp: 2029-01-21→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2021-02-22$7.84/sh+5,000$39,200→ 20,212 total - Sale
Common Stock
2021-02-22$14.72/sh−5,000$73,582→ 15,212 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.31 to $15.03, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The shares underlying the option are scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2019, subject to continued service.